HRMY
Live chart
What they do
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Grades vs sector
Momentum71st pct in sectorB
Percentile within its GICS sector across the S&P 1500.
Growth88th pct in sectorA
Percentile within its GICS sector across the S&P 1500.
Value97th pct in sectorA+
Percentile within its GICS sector across the S&P 1500.
Profitability77th pct in sectorB+
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.01 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
cheaper
cheaper
cheaper
cheaper
cheaper
cheaper
Forward EPS $7.00 vs trailing $3.10 (+126% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score 5.7 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $868.5M | $158.7M | $347.9M |
| 2024 | $714.7M | $145.5M | $218.7M |
| 2023 | $582.0M | $128.9M | $219.1M |
| 2022 | $437.9M | $181.5M | $144.3M |
| 2021 | $305.4M | $34.6M | $98.3M |
| 2020 | $159.7M | $-36.9M | $-3.0M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +25.6%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | 1.15 | 1.50 | +30.6% |
| 2026-05-07 | 0.93 | 0.79 | -15.9% |
| 2026-02-24 | 1.07 | 0.57 | -46.5% |
| 2025-11-04 | 0.86 | 1.08 | +25.4% |
| 2025-08-05 | 0.96 | 0.92 | -3.7% |
| 2025-05-06 | 0.91 | 1.03 | +12.7% |
| 2025-02-25 | 0.82 | 1.08 | +32.2% |
| 2024-10-29 | 0.88 | 1.03 | +16.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $261.3M | +30.3% |
| 2026-03-31 | $215.4M | – |
| 2025-12-31 | $243.8M | – |
| 2025-09-30 | $239.5M | – |
| 2025-06-30 | $200.5M | – |
Analyst actions
PT $50
PT $55
PT $50
PT $60
PT $34
PT $50
Stats refreshed 2026-10-21 11:28:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.